Page last updated: 2024-08-24

halofuginone and Chronic Illness

halofuginone has been researched along with Chronic Illness in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cypel, M; Guan, Z; Hirayama, S; Hwang, DM; Juvet, SC; Keller, TL; Keshavjee, S; Liu, M; Martinu, T; Matsuda, Y; Oishi, H; Saito, T; Sato, M; Whitman, MR1
Chen, W; Cheng, H; Li, Z; Pan, B; Song, G; Tian, J; Xu, K; Zeng, L1

Other Studies

2 other study(ies) available for halofuginone and Chronic Illness

ArticleYear
Halofuginone treatment reduces interleukin-17A and ameliorates features of chronic lung allograft dysfunction in a mouse orthotopic lung transplant model.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2016, Volume: 35, Issue:4

    Topics: Animals; Chronic Disease; Disease Models, Animal; Graft Rejection; Interleukin-17; Lung Transplantation; Male; Mice; Mice, Inbred C57BL; Piperidines; Protein Synthesis Inhibitors; Quinazolinones; Th17 Cells; Transplantation, Homologous

2016
Halofugine prevents cutaneous graft versus host disease by suppression of Th17 differentiation.
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Transplantation; Cell Differentiation; Chronic Disease; Cytokines; Female; Graft vs Host Disease; Male; Mice; Mice, Inbred BALB C; Piperidines; Quinazolinones; Skin Diseases; Th17 Cells; Time Factors; Transplantation, Homologous

2012